Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Johnson and Johnson
Baxter
Boehringer Ingelheim
Covington
US Department of Justice
McKesson
Medtronic
Julphar
Argus Health

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,871,779

« Back to Dashboard

Which drugs does patent 8,871,779 protect, and when does it expire?

Patent 8,871,779 protects OPANA ER and is included in one NDA.

This patent has eleven patent family members in nine countries.
Summary for Patent: 8,871,779
Title:Process for preparing morphinan-6-one products with low levels of .alpha.,.beta.-unsaturated ketone compounds
Abstract: The present invention generally relates to processes for preparing highly pure morphinan-6-one products. The processes involve reducing the concentration of .alpha.,.beta.-unsaturated ketone compounds present as impurities in morphinan 6 one products or reaction mixtures including morphinan 6 one compounds by treatment with a sulfur-containing compound. (A) ##STR00001##
Inventor(s): Buehler; Henry J. (St. Louis, MO), Dummitt; William E. (St. Louis, MO), Mannino; Anthony (Maryland Heights, MO), Aubuchon; Dennis C. (Arnold, MO), Gu; Hong (Oak Park, CA)
Assignee: Mallinckrodt LLC (Hazelwood, MO)
Application Number:11/915,606
Patent Claim Types:
see list of patent claims
Compound; Formulation;

Drugs Protected by US Patent 8,871,779

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-001 Dec 9, 2011 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-002 Dec 9, 2011 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-003 Dec 9, 2011 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-004 Dec 9, 2011 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-005 Dec 9, 2011 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-006 Dec 9, 2011 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Endo Pharms OPANA ER oxymorphone hydrochloride TABLET, EXTENDED RELEASE;ORAL 201655-007 Dec 9, 2011 DISCN Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,871,779

PCT Information
PCT FiledMarch 02, 2007PCT Application Number:PCT/US2007/005256
PCT Publication Date:September 13, 2007PCT Publication Number: WO2007/103105

Non-Orange Book US Patents Family Members for Patent 8,871,779

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,748,611 Processes for preparing morphinan-6-one products with low levels of alpha beta-unsaturated compounds ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,871,779

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Mexico 2008010921 ➤ Sign Up
Japan 2013173765 ➤ Sign Up
Japan 5695296 ➤ Sign Up
Japan 2009528366 ➤ Sign Up
European Patent Office 1994034 ➤ Sign Up
Germany 602007003197 ➤ Sign Up
China 101395159 ➤ Sign Up
Canada 2644095 ➤ Sign Up
Australia 2007224221 ➤ Sign Up
Austria 448231 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Healthtrust
US Army
Cerilliant
Boehringer Ingelheim
McKesson
Fuji
Harvard Business School
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot